Print  |  Close

AFP?³³²T in Advanced HCC


Active: Yes
Cancer Type: Liver Cancer / Hepatoblastoma NCT ID: NCT03132792
Trial Phases: Phase I Protocol IDs: ADP-0033-001 (primary)
NCI-2017-01188
Eligibility: 18 - 75 Years, Male and Female Study Type: Treatment
Study Sponsor: Adaptimmune Limited
NCI Full Details: http://clinicaltrials.gov/show/NCT03132792

Summary

This first time in human study is intended for men and women between 18 and 75 years of age
who have advanced liver cancer which has grown or returned after being treated or another AFP
expressing tumor. Those who did not tolerate or refused other therapies may also participate.
The purpose of this study is to test the safety of genetically changed T cells that target
alpha-fetoprotein (AFP) and find out what effects, if any, they have in subjects with liver
cancer or other AFP expressing tumor types. This study is for subjects who have a blood test
positive for appropriate HLA-A*02 P Group and have adequate AFP protein in blood or tumor,
and whose noncancerous liver tissue has very little AFP protein (Liver only).

The study will take the subject's T cells, which are a natural type of immune cell in the
blood, and send them to a laboratory to be modified. The changed T cells used in this study
will be the subject's own T cells that have been genetically changed with the aim of
attacking and destroying cancer cells.

The manufacturing of T cells takes about 1 month to complete. The T cells will be given back
to the subject through an intravenous infusion after 3 days of chemotherapy. The study will
evaluate three different cell dose levels in order to find out the target cell dose. Once the
target cell dose is determined, additional subjects will be enrolled to further test the
safety and effects at this cell dose.

Subjects will be hospitalized for at least 1 week after receiving their T cells back and then
seen frequently by the Study Physician for the next 6 months. After that, subjects will be
seen every three months. If subjects have disease progression or withdraw from the study,
they will then be entered into a long-term follow up for safety monitoring. In long-term
follow up, subjects will be seen every 6 months by their Study Physician for the first 5
years after the T cell infusion and annually for the next 10 years.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.